Last reviewed · How we verify
Usual dose adjustment of enoxaparin
Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.
Enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Venous thromboembolism prophylaxis, Acute deep vein thrombosis treatment, Acute pulmonary embolism treatment.
At a glance
| Generic name | Usual dose adjustment of enoxaparin |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa and Factor IIa (via antithrombin III) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Enoxaparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of coagulation factors Xa and IIa. This prevents thrombin generation and fibrin clot formation. Dose adjustment protocols are used to optimize anticoagulation based on patient factors such as renal function, body weight, and clinical indication.
Approved indications
- Venous thromboembolism prophylaxis
- Acute deep vein thrombosis treatment
- Acute pulmonary embolism treatment
- Acute coronary syndrome (unstable angina and non-ST-segment elevation myocardial infarction)
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
- Osteoporosis (with long-term use)
Key clinical trials
- Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (PHASE4)
- AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia (PHASE3)
- Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies (PHASE2, PHASE3)
- Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: